Literature DB >> 15685209

A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations.

Michael S Crane1, Adriano G Rossi, Ian L Megson.   

Abstract

1. Nitric oxide (NO) is a potent inhibitor of platelet activation, that inhibits the agonist-induced increase in cytosolic Ca2+ concentration through both cGMP-dependent and independent pathways. However, the NO-related (NOx) species responsible for cGMP-independent signalling in platelets is unclear. We tested the hypothesis that extracellular NO, but not NO+ or peroxynitrite, generated in the extracellular compartment is responsible for cGMP-independent inhibition of platelet activation via inhibition of Ca2+ signalling. 2. Concentration-response curves for diethylamine diazeniumdiolate (DEA/NO; a spontaneous NO generator), S-nitroso-N-valerylpenicillamine (SNVP; an S-nitrosothiol) and 3-morpholinosydnonomine (SIN-1; a peroxynitrite generator) were generated in platelet-rich plasma (PRP) and washed platelets (WP) in the presence and absence of a supramaximal concentration of the soluble guanylate cyclase inhibitor, ODQ (20 microM). All three NOx donors displayed cGMP-independent inhibition of platelet aggregation in PRP, but only DEA/NO exhibited cGMP-independent inhibition of aggregation in WP. 3. Analysis of NO generation using an isolated NO-electrode revealed that cGMP-independent effects coincided with the generation of substantial levels of extracellular NO (>40 nM) from the NOx donors. 4. Reconstitution of WP with plasma factors indicated that the copper-containing plasma protein, caeruloplasmin (CP), catalysed the release of NO from SNVP, while Cu/Zn superoxide dismutase (SOD) unmasked NO generated from SIN-1. The increased generation of extracellular NO correlated with a switch to cGMP-independent effects with both NOx donors. 5. Analysis of Fura-2 loaded WP revealed that only DEA/NO inhibited Ca2+ signalling in platelets via a cGMP-independent mechanism. However, preincubation of SNVP and SIN-1 with CP and SOD, respectively, induced cGMP-independent inhibition of intraplatelet Ca2+ trafficking by the NOx donors. 6. Taken together, our data suggest that extracellular NO (>40 nM) is required for cGMP-independent inhibition of platelet activation. Plasma constituents may play an important pharmacological role in activating cGMP-independent signalling by S-nitrosothiols or peroxynitrite generators.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685209      PMCID: PMC1576067          DOI: 10.1038/sj.bjp.0706110

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  64 in total

1.  An improved colorimetric enzymatic assay of ceruloplasmin.

Authors:  H A RAVIN
Journal:  J Lab Clin Med       Date:  1961-07

2.  The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1987-11-13       Impact factor: 3.575

Review 3.  Cytosolic calcium in platelet activation.

Authors:  T J Rink
Journal:  Experientia       Date:  1988-02-15

Review 4.  The role of platelet calcium.

Authors:  E H Murer
Journal:  Semin Hematol       Date:  1985-10       Impact factor: 3.851

5.  Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.

Authors:  L J Ignarro; H Lippton; J C Edwards; W H Baricos; A L Hyman; P J Kadowitz; C A Gruetter
Journal:  J Pharmacol Exp Ther       Date:  1981-09       Impact factor: 4.030

6.  Endothelium-derived relaxant factor inhibits platelet activation.

Authors:  R Busse; A Lückhoff; E Bassenge
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

7.  Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Lancet       Date:  1987-11-07       Impact factor: 79.321

8.  The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

9.  Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelets.

Authors:  S Nakashima; T Tohmatsu; H Hattori; Y Okano; Y Nozawa
Journal:  Biochem Biophys Res Commun       Date:  1986-03-28       Impact factor: 3.575

10.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

View more
  12 in total

Review 1.  Routes for formation of S-nitrosothiols in blood.

Authors:  Enika Nagababu; Joseph M Rifkind
Journal:  Cell Biochem Biophys       Date:  2013-11       Impact factor: 2.194

Review 2.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

Review 3.  S-nitrosothiols as selective antithrombotic agents - possible mechanisms.

Authors:  M P Gordge; F Xiao
Journal:  Br J Pharmacol       Date:  2010-03-08       Impact factor: 8.739

Review 4.  S-nitrosylation in cardiovascular signaling.

Authors:  Brian Lima; Michael T Forrester; Douglas T Hess; Jonathan S Stamler
Journal:  Circ Res       Date:  2010-03-05       Impact factor: 17.367

5.  Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets.

Authors:  Catriona M Turnbull; Clara Cena; Roberta Fruttero; Alberto Gasco; Adriano G Rossi; Ian L Megson
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

Review 6.  Nitric oxide regulation of protein trafficking in the cardiovascular system.

Authors:  Charles J Lowenstein
Journal:  Cardiovasc Res       Date:  2007-04-03       Impact factor: 10.787

7.  Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase.

Authors:  Andreas Friebe; Evanthia Mergia; Oliver Dangel; Alexander Lange; Doris Koesling
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

Review 8.  Hypertension in pregnancy: natural history and treatment options.

Authors:  L Foo; J Tay; C C Lees; C M McEniery; I B Wilkinson
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

Review 9.  The nitric oxide pathway and possible therapeutic options in pre-eclampsia.

Authors:  Tamanrit Johal; Christoph C Lees; Thomas R Everett; Ian B Wilkinson
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

10.  S-Nitrosoglutathione improves haemodynamics in early-onset pre-eclampsia.

Authors:  Thomas R Everett; Ian B Wilkinson; Amita A Mahendru; Carmel M McEniery; Stephen F Garner; Alison H Goodall; Christoph C Lees
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.